9amHealth Expands Services to Autoimmune Care and Introduces 9amRx Direct to Reduce Medication Costs

9amHealth's Bold Move into Autoimmune Care

In an exciting development for healthcare management, 9amHealth, a prominent specialty care provider, has declared its entry into the field of autoimmune disorders along with the launch of its innovative offering, 9amRx Direct. This new initiative aims to tackle the skyrocketing costs associated with high-priced medications, particularly focusing on autoimmune treatments.

Addressing a Critical Need

According to recent statistics, over 53% of the total prescription spending in the United States is consumed by specialty medications. A significant contributor to this figure are inflammatory and autoimmune diseases, which account for approximately one-third of prescription expenditures. The annual costs for treating these chronic conditions can be staggering, with biologic therapies ranging from $21,000 to $47,000 per patient. As such, there is a pressing need for solutions that not only simplify treatment but also provide economic relief to employers managing these complex health issues.

A Comprehensive Care Model

9amHealth’s new autoimmune care program strategically leverages its existing cardiometabolic model. It seeks to offer integrated support for individuals battling conditions such as rheumatoid arthritis and psoriatic arthritis. The multidisciplinary care team, comprising various health professionals, is designed to deliver ongoing assistance by managing pain, fatigue, and flare-ups effectively.

Pharmacists also play a crucial role in this model, ensuring that patients have help navigating their treatment choices, managing medication use, and transitioning to biosimilars when clinically necessary. As noted by Paul Geevarghese, PharmD and Co-CEO of 9amHealth, the complexities and high costs associated with both inflammatory autoimmune and cardiometabolic conditions warrant a unified approach to healthcare management.

Introducing 9amRx Direct

In addition to their specialization in autoimmune care, 9amHealth is rolling out 9amRx Direct, a service that allows employers to issue high-cost medications outside the conventional pharmacy framework. This innovative offering is designed to enhance affordability, providing access to medications priced 30-50% lower than average industry standards. Supported by claims administration and billing solutions, 9amRx Direct is initially available for GLP-1 weight-loss medications, with plans to expand into autoimmune specialty medications in the coming year.

Internal projections indicate that employers could see a return on investment as high as 4x within the first year of using 9amRx Direct. Together with its specialty clinics, this new medication access solution equips employers with a coordinated approach to managing specialty care effectively while improving overall health outcomes.

Future Forward

9amHealth aims to revolutionize how companies manage chronic healthcare conditions and their associated costs. As the healthcare landscape evolves and the demand for cheaper, yet effective, treatment options increases, 9amHealth's offerings position them as leaders in a much-needed transformation in how chronic health issues, particularly autoimmune diseases, are addressed.

To stay informed about these developments, employers and interested parties can visit 9am.health or connect in person with the 9amHealth team at the upcoming HLTH conference in Las Vegas. This specialty chronic care platform not only aspires to enhance health outcomes for its members but also aims to alleviate healthcare costs for employers and health plans alike. Founded in 2021, 9amHealth is supported by notable healthcare investors, including Define Ventures and 7wire Ventures, showcasing confidence in its innovative approach to healthcare delivery.